SPDR S&P Pharmaceuticals ETF (XPH) Holdings
XPH holdings summary
as of Oct 25, 2026- Holdings
- 61 positions listed
- Top 10 weight
- 24.4% of net assets
- Effective holdings
- 54 equal-weight equivalent
- Largest holding
- MANE 2.80% Veradermics, Incorporated
- Annual turnover
- 50.8% of the portfolio traded
All XPH holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | MANE | Veradermics, Incorporated | Healthcare | 2.80% | $12.3M | $4.55B | — |
| 2 | XERS | Xeris Biopharma Holdings, Inc. | Healthcare | 2.68% | $11.7M | $1.88B | — |
| 3 | PCRX | Pacira BioSciences, Inc. | Healthcare | 2.56% | $11.2M | $1.45B | 103.8 |
| 4 | LLY | Eli Lilly and Company | Healthcare | 2.42% | $10.6M | $1.12T | 42.2 |
| 5 | AMRX | Amneal Pharmaceuticals, Inc. | Healthcare | 2.42% | $10.6M | $6.68B | 39.1 |
| 6 | PRGO | Perrigo Company plc | Healthcare | 2.40% | $10.5M | $2.30B | — |
| 7 | MAZE | Maze Therapeutics, Inc. | Healthcare | 2.33% | $10.2M | $1.53B | — |
| 8 | ZTS | Zoetis Inc. | Healthcare | 2.27% | $10.0M | $32.80B | 13.1 |
| 9 | PFE | Pfizer Inc. | Healthcare | 2.27% | $9.9M | $168.60B | 38.9 |
| 10 | ANIP | ANI Pharmaceuticals, Inc. | Healthcare | 2.22% | $9.8M | $1.66B | 15.6 |
| 11 | RPRX | Royalty Pharma plc | Healthcare | 2.20% | $9.7M | $35.22B | 32.4 |
| 12 | VTRS | Viatris Inc. | Healthcare | 2.19% | $9.6M | $21.43B | — |
| 13 | SEPN | Septerna, Inc. | Healthcare | 2.15% | $9.5M | $1.70B | — |
| 14 | LGND | Ligand Pharmaceuticals Incorporated | Healthcare | 2.15% | $9.4M | $5.89B | 31.1 |
| 15 | JNJ | Johnson & Johnson | Healthcare | 2.04% | $9.0M | $615.87B | 38.8 |
| 16 | INVA | Innoviva, Inc. | Healthcare | 2.02% | $8.9M | $1.50B | 4.9 |
| 17 | SUPN | Supernus Pharmaceuticals, Inc. | Healthcare | 2.02% | $8.9M | $2.21B | — |
| 18 | DFTX | Definium Therapeutics, Inc. | Healthcare | 2.02% | $8.8M | $4.31B | — |
| 19 | COLL | Collegium Pharmaceutical, Inc. | Healthcare | 2.00% | $8.8M | $755.0M | 18.3 |
| 20 | OGN | Organon & Co. | Healthcare | 1.99% | $8.7M | $3.61B | 17.6 |
| 21 | ELAN | Elanco Animal Health Incorporated | Healthcare | 1.97% | $8.7M | $11.76B | — |
| 22 | INDV | Indivior PLC | Healthcare | 1.96% | $8.6M | $3.83B | 11.6 |
| 23 | MRK | Merck & Co., Inc. | Healthcare | 1.96% | $8.6M | $360.08B | 115.8 |
| 24 | PBH | Prestige Consumer Healthcare Inc. | Healthcare | 1.94% | $8.5M | $2.36B | 14.0 |
| 25 | EWTX | Edgewise Therapeutics, Inc. | Healthcare | 1.88% | $8.3M | $4.04B | — |
| 26 | BMY | Bristol-Myers Squibb Company | Healthcare | 1.88% | $8.2M | $122.05B | 13.2 |
| 27 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | 1.80% | $7.9M | $13.65B | 14.4 |
| 28 | HRMY | Harmony Biosciences Holdings, Inc. | Healthcare | 1.78% | $7.8M | $2.21B | 12.2 |
| 29 | ETON | Eton Pharmaceuticals, Inc. | Healthcare | 1.77% | $7.8M | $1.44B | 125.8 |
| 30 | OMER | Omeros Corporation | Healthcare | 1.76% | $7.7M | $1.17B | 13.3 |
| 31 | AMLX | Amylyx Pharmaceuticals, Inc. | Healthcare | 1.75% | $7.7M | $3.31B | — |
| 32 | TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | 1.72% | $7.5M | $3.19B | — |
| 33 | MBX | MBX Biosciences, Inc. | Healthcare | 1.60% | $7.0M | $2.39B | — |
| 34 | TRVI | Trevi Therapeutics, Inc. | Healthcare | 1.59% | $7.0M | $1.69B | — |
| 35 | HROW | Harrow Health, Inc. | Healthcare | 1.59% | $7.0M | $1.02B | — |
| 36 | AMPH | Amphastar Pharmaceuticals, Inc. | Healthcare | 1.52% | $6.7M | $1.10B | 15.3 |
| 37 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 1.49% | $6.5M | $8.23B | — |
| 38 | CORT | Corcept Therapeutics Incorporated | Healthcare | 1.49% | $6.5M | $11.91B | 244.8 |
| 39 | ALMS | Alumis Inc. | Healthcare | 1.46% | $6.4M | $792.1M | — |
| 40 | ELVN | Enliven Therapeutics, Inc. | Healthcare | 1.46% | $6.4M | $2.73B | — |
| 41 | NUVB | Nuvation Bio Inc. | Healthcare | 1.45% | $6.4M | $1.56B | — |
| 42 | LBRX | LB Pharmaceuticals Inc | Healthcare | 1.45% | $6.4M | $1.19B | 367.4 |
| 43 | KMPH | KemPharm Inc | Healthcare | 1.42% | $6.2M | — | — |
| 44 | PAHC | Phibro Animal Health Corporation | Healthcare | 1.38% | $6.1M | $1.58B | 16.0 |
| 45 | CRMD | CorMedix Inc. | Healthcare | 1.33% | $5.8M | $565.9M | 3.5 |
| 46 | LQDA | Liquidia Corporation | Healthcare | 1.30% | $5.7M | $3.07B | 24.7 |
| 47 | WVE | Wave Life Sciences Ltd. | Healthcare | 1.23% | $5.4M | $616.8M | — |
| 48 | RAPP | Rapport Therapeutics, Inc. | Healthcare | 1.18% | $5.2M | $1.32B | — |
| 49 | OCUL | Ocular Therapeutix, Inc. | Healthcare | 1.16% | $5.1M | $1.51B | — |
| 50 | ANRO | Alto Neuroscience, Inc. | Healthcare | 1.13% | $5.0M | $861.0M | — |
| 51 | AQST | Aquestive Therapeutics, Inc. | Healthcare | 1.03% | $4.5M | $474.4M | — |
| 52 | PHAT | Phathom Pharmaceuticals, Inc. | Healthcare | 0.91% | $4.0M | $559.8M | — |
| 53 | ACRS | Aclaris Therapeutics, Inc. | Healthcare | 0.87% | $3.8M | $482.8M | — |
| 54 | RLMD | Relmada Therapeutics, Inc. | Healthcare | 0.86% | $3.8M | $330.7M | — |
| 55 | AVLN | Avalyn Pharma Inc. | Healthcare | 0.83% | $3.7M | $1.05B | — |
| 56 | ARVN | Arvinas, Inc. | Healthcare | 0.75% | $3.3M | $449.7M | 26.8 |
| 57 | EOLS | Evolus, Inc. | Healthcare | 0.67% | $3.0M | $469.0M | — |
| 58 | LXRX | Lexicon Pharmaceuticals, Inc. | Healthcare | 0.65% | $2.9M | $676.3M | — |
| 59 | BIOA | BioAge Labs, Inc | Healthcare | 0.54% | $2.4M | $222.1M | — |
| 60 | CTNM | Contineum Therapeutics, Inc. | Healthcare | 0.41% | $1.8M | $266.4M | — |
| 61 | EYPT | EyePoint Pharmaceuticals, Inc. | Healthcare | 0.09% | $393,746.07 | $250.7M | — |
Weights as a percentage of net assets. Value held = weight × net assets ($439.0M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
XPH sector breakdown
Sum of the weights of the holdings in each sector.
XPH top industries
XPH overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| DIA | SPDR Dow Jones Industrial Average ETF | 3.8% | 2 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 3.4% | 7 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 3.4% | 58 of 2,941 | 0.03% |
| IWM | iShares Russell 2000 ETF | 2.4% | 47 of 1,962 | 0.19% |
| VXUS | Vanguard Total International Stock ETF | 0.0% | 1 of 8,035 | 0.05% |
| QQQ | Invesco QQQ ETF | 0.0% | 0 of 101 | 0.17% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the XPH portfolio
SPDR S&P Pharmaceuticals ETF holds 61 positions. The ten largest make up 24.4% of the fund and the top 50 92.5%, so it behaves like a portfolio of about 54 equally weighted stocks. The biggest positions are Veradermics, Incorporated (2.80%), Xeris Biopharma Holdings, Inc. (2.68%), Pacira BioSciences, Inc. (2.56%), Eli Lilly and Company (2.42%), Amneal Pharmaceuticals, Inc. (2.42%).
By sector, Healthcare is 100.1%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: XPH chart, XPH performance, XPH dividends, XPH overview.
XPH holdings FAQ
How many holdings does XPH have?
XPH holds 61 positions as of October 25, 2026.
What are the top 10 holdings of XPH?
The ten largest holdings are Veradermics, Incorporated (2.80%), Xeris Biopharma Holdings, Inc. (2.68%), Pacira BioSciences, Inc. (2.56%), Eli Lilly and Company (2.42%), Amneal Pharmaceuticals, Inc. (2.42%), Perrigo Company plc (2.40%), Maze Therapeutics, Inc. (2.33%), Zoetis Inc. (2.27%), Pfizer Inc. (2.27%), ANI Pharmaceuticals, Inc. (2.22%). Together they are 24.4% of the fund.
What percentage of XPH is Veradermics, Incorporated?
Veradermics, Incorporated is the largest holding at 2.80% of net assets, about $12.3M of the fund's $439.0M.
How concentrated is XPH?
The top 10 holdings are 24.4% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) XPH behaves like a portfolio of about 54 equally weighted stocks.